9 November 2017  
EMA/738556/2017  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Orkambi 
lumacaftor / ivacaftor 
On 9 November 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Orkambi. The marketing authorisation holder for this medicinal product is Vertex Pharmaceuticals 
(Europe) Ltd. 
The CHMP adopted an extension to the existing indication as follows2: 
Orkambi is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 6 years and older who 
are homozygous for the F508del mutation in the CFTR gene (see sections 4.2, 4.4 and 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
